Clinical-demographic and adverse-event characterization during treatment with Heberprot-P
Introduction: Heberprot-P is a novel drug that has come for the reduction of amputation risks; like any drug it is not devoid of adverse events. Objectives: to characterize patients during Heberprot-P treatment according to demographic and clinical variables, as well as to describe adverse events re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Editorial Ciencias Médicas
2020-10-01
|
| Series: | Acta Médica del Centro |
| Subjects: | |
| Online Access: | http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/1254 |
| _version_ | 1811243999194775552 |
|---|---|
| author | Perla María Trujillo Pedroza Asiris Mendoza Molina Magdenis Rivalta Morfa Maite George Arce Linnet Castellón Martínez |
| author_facet | Perla María Trujillo Pedroza Asiris Mendoza Molina Magdenis Rivalta Morfa Maite George Arce Linnet Castellón Martínez |
| author_sort | Perla María Trujillo Pedroza |
| collection | DOAJ |
| description | Introduction: Heberprot-P is a novel drug that has come for the reduction of amputation risks; like any drug it is not devoid of adverse events.
Objectives: to characterize patients during Heberprot-P treatment according to demographic and clinical variables, as well as to describe adverse events reported during therapy.
Methods: a longitudinal study was conducted at the Comprehensive Care Clinic for patients with diabetic foot ulcers at "Policlínico Manuel Piti Fajardo" in Santo Domingo, Villa Clara, between January 2017 and September 2019. The sample was 104 patients who were applied the Heberprot-P. Variables used were: age, sex, Wagner's classification, etiopathogenic classification of the diabetic foot, treatment effectiveness and reported adverse events (frequency, intensity, severity and causality relationship were addressed).
Results: females and patients over 60 years old predominated (67.31%). According to Wagner's classification for diabetic foot ulcer, grade 1 prevailed (73.08%), and according to etiopathogenesis, patients with neuroinfective foot prevailed (58.65%). Total effectiveness of treatment was 90.38%. The most frequent adverse events were burning, pain and headache. Adverse events dependent on the mode of administration and the product itself (burning and pain) predominated, mostly of mild intensity and defined causality.
Conclusions: the beneficial effect of Heberprot-P in diabetic foot ulcers to achieve granulation was confirmed. Adverse events associated with treatment present similar characteristics to those reported at national and international level. |
| first_indexed | 2024-04-12T14:18:09Z |
| format | Article |
| id | doaj.art-0788e45a784f4398a9cdf22453ecc4e5 |
| institution | Directory Open Access Journal |
| issn | 2709-7927 |
| language | Spanish |
| last_indexed | 2024-04-12T14:18:09Z |
| publishDate | 2020-10-01 |
| publisher | Editorial Ciencias Médicas |
| record_format | Article |
| series | Acta Médica del Centro |
| spelling | doaj.art-0788e45a784f4398a9cdf22453ecc4e52022-12-22T03:29:39ZspaEditorial Ciencias MédicasActa Médica del Centro2709-79272020-10-01144517529983Clinical-demographic and adverse-event characterization during treatment with Heberprot-PPerla María Trujillo Pedroza0Asiris Mendoza Molina1Magdenis Rivalta Morfa2Maite George Arce3Linnet Castellón Martínez4Policlínico Docente "Manuel Piti Fajardo"Policlínico Docente "Manuel Piti Fajardo"Policlínico Docente "Manuel Piti Fajardo"Policlínico Docente "Manuel Piti Fajardo"Policlínico Docente "Manuel Piti Fajardo"Introduction: Heberprot-P is a novel drug that has come for the reduction of amputation risks; like any drug it is not devoid of adverse events. Objectives: to characterize patients during Heberprot-P treatment according to demographic and clinical variables, as well as to describe adverse events reported during therapy. Methods: a longitudinal study was conducted at the Comprehensive Care Clinic for patients with diabetic foot ulcers at "Policlínico Manuel Piti Fajardo" in Santo Domingo, Villa Clara, between January 2017 and September 2019. The sample was 104 patients who were applied the Heberprot-P. Variables used were: age, sex, Wagner's classification, etiopathogenic classification of the diabetic foot, treatment effectiveness and reported adverse events (frequency, intensity, severity and causality relationship were addressed). Results: females and patients over 60 years old predominated (67.31%). According to Wagner's classification for diabetic foot ulcer, grade 1 prevailed (73.08%), and according to etiopathogenesis, patients with neuroinfective foot prevailed (58.65%). Total effectiveness of treatment was 90.38%. The most frequent adverse events were burning, pain and headache. Adverse events dependent on the mode of administration and the product itself (burning and pain) predominated, mostly of mild intensity and defined causality. Conclusions: the beneficial effect of Heberprot-P in diabetic foot ulcers to achieve granulation was confirmed. Adverse events associated with treatment present similar characteristics to those reported at national and international level.http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/1254heberprot-ppie diabéticoreacciones adversas |
| spellingShingle | Perla María Trujillo Pedroza Asiris Mendoza Molina Magdenis Rivalta Morfa Maite George Arce Linnet Castellón Martínez Clinical-demographic and adverse-event characterization during treatment with Heberprot-P Acta Médica del Centro heberprot-p pie diabético reacciones adversas |
| title | Clinical-demographic and adverse-event characterization during treatment with Heberprot-P |
| title_full | Clinical-demographic and adverse-event characterization during treatment with Heberprot-P |
| title_fullStr | Clinical-demographic and adverse-event characterization during treatment with Heberprot-P |
| title_full_unstemmed | Clinical-demographic and adverse-event characterization during treatment with Heberprot-P |
| title_short | Clinical-demographic and adverse-event characterization during treatment with Heberprot-P |
| title_sort | clinical demographic and adverse event characterization during treatment with heberprot p |
| topic | heberprot-p pie diabético reacciones adversas |
| url | http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/1254 |
| work_keys_str_mv | AT perlamariatrujillopedroza clinicaldemographicandadverseeventcharacterizationduringtreatmentwithheberprotp AT asirismendozamolina clinicaldemographicandadverseeventcharacterizationduringtreatmentwithheberprotp AT magdenisrivaltamorfa clinicaldemographicandadverseeventcharacterizationduringtreatmentwithheberprotp AT maitegeorgearce clinicaldemographicandadverseeventcharacterizationduringtreatmentwithheberprotp AT linnetcastellonmartinez clinicaldemographicandadverseeventcharacterizationduringtreatmentwithheberprotp |